The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Kiniksa Pharmaceuticals International Plc shares valued at $502,680 were sold by Ragosa Mark on Jan 08 ’26. At $41.89 per share, Ragosa Mark sold 12,000 shares. The insider’s holdings dropped to 19,086 shares worth approximately $0.76 million following the completion of this transaction.
Also, Quart Barry D sold 20,129 shares, netting a total of over 835,555 in proceeds. Following the sale of shares at $41.51 each, the insider now holds 12,546 shares.
Before that, Tessari Eben had sold 12,048 shares from its account. In a trade valued at $500,715, the CHIEF OPERATING OFFICER traded Kiniksa Pharmaceuticals International Plc shares for $41.56 each. Upon closing the transaction, the insider’s holdings decreased to 12,048 shares, worth approximately $0.66 million.
As published in their initiating research note from TD Cowen on September 29, 2025, Kiniksa Pharmaceuticals International Plc [KNSA] has been a Buy and the price target has been revised to $60. Analysts at Citigroup started covering the stock with ‘”a Buy”‘ outlook in a report released in mid March. As of September 13, 2024, Jefferies has initiated its “Buy” rating for KNSA. Earlier on May 03, 2024, Wells Fargo initiated its rating. Their recommendation was “an Overweight” for KNSA stock.
Analyzing KNSA Stock Performance
On last trading session, Kiniksa Pharmaceuticals International Plc [NASDAQ: KNSA] rose 2.49% to $39.56. The stock’s lowest price that day was $37.56, but it reached a high of $39.69 in the same session. During the last five days, there has been a drop of approximately -6.74%. Over the course of the year, Kiniksa Pharmaceuticals International Plc shares have jumped approximately 117.72%.
Is Kiniksa Pharmaceuticals International Plc subject to short interest?
Stocks of Kiniksa Pharmaceuticals International Plc saw a sharp rise in short interest on 2025-12-31 jumping by 0.77 million shares to 3.57 million. Data from Yahoo Finance shows that the short interest on 2025-11-28 was 2.8 million shares. A jump of 21.54% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 9.17 of the overall float, the days-to-cover ratio (short ratio) jumped to 9.17.
Which companies own the most shares of Kiniksa Pharmaceuticals International Plc (KNSA)?
In terms of Kiniksa Pharmaceuticals International Plc share price expectations, FactSet research, analysts set an average price target of 54 in the next 12 months, up nearly 39.9% from the previous closing price of $38.6. Analysts anticipate Kiniksa Pharmaceuticals International Plc stock to reach 55 by 2026, with the lowest price target being 50. In spite of this, 1 analysts ranked Kiniksa Pharmaceuticals International Plc stock as Buy at the end of 2026. On June 29, 2020, BofA Securities assigned a price target of “a Buy” to the stock and reiterated coverage with a $40.
